ArticleResearch square2023

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis.

Julie Williamson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.